Clinical effect of simvastatin combined with fenofibrate in the treatment of hyperlipidemia.

Objective To observe the clinical effect and safety of simvastatin combined with fenofibrate in the treatment of mixed hyperlipidemia. Methods One hundred and twenty-six patients with mixed hyperlipidemia were randomly divided into two groups, each with 63 cases. Patients in the observation group took orally micronised fenofibrate 100 mg in the morning and simvastatin 10 mg at night, while those in the control group received simvastatin 20 mg at night. All the patients were treated for 12 weeks. The rate of change of the major lipid parameters before and after treatment was observed, as well as the clinical efficacy, incidence of compliances and adverse reactions. Results For lipid parameters, the levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), high density lipoprotein cholesterol (HDL-C) were significantly lower in the observation group than the control group (t=6.304 8, 6.694 6, 31.768 1, 6.281 0, respectively, P0.01). In the comparison of clinical efficacy, the total effective rate in the observation group was significantly higher than that in the control group (χ2=6.98, P0.01). The general ratio of reaching standard for LDL-C、TG、TC were significantly higher in the observation group (χ2=4.67, 6.30, 5.03, P0.05). Increased alanine amino transferase (ALT) levels were found in two patients of the observation group and three patients of the control group, lower than 3 times of the normal value, with no statistically significant difference. The two groups showed no significant difference in creatine kinase (CK), with no symptoms of myopathy. Conclusion Simvastatin combined with fenofibrate is quite effective and safe for treating mixed hyperlipidemia.